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The purpose of this study was to demonstrate spatial control of osteoblast differentiation in vitro and bone
formation in vivo using inkjet bioprinting technology and to create three-dimensional persistent bio-ink patterns
of bone morphogenetic protein-2 (BMP-2) and its modifiers immobilized within microporous scaffolds. Semi-
circular patterns of BMP-2 were printed within circular DermaMatrix human allograft scaffold constructs. The
contralateral halves of the constructs were unprinted or printed with BMP-2 modifiers, including the BMP-2
inhibitor, noggin. Printed bio-ink pattern retention was validated using fluorescent or 125I-labeled bio-inks.
Mouse C2C12 progenitor cells cultured on patterned constructs differentiated in a dose-dependent fashion
toward an osteoblastic fate in register to BMP-2 patterns. The fidelity of spatial restriction of osteoblastic
differentiation at the boundary between neighboring BMP-2 and noggin patterns improved in comparison with
patterns without noggin. Acellular DermaMatrix constructs similarly patterned with BMP-2 and noggin were
then implanted into a mouse calvarial defect model. Patterns of bone formation in vivo were comparable with
patterned responses of osteoblastic differentiation in vitro. These results demonstrate that three-dimensional
biopatterning of a growth factor and growth factor modifier within a construct can direct cell differentiation
in vitro and tissue formation in vivo in register to printed patterns.
Introduction
Spatial patterning of cell function occurs duringembryogenesis and throughout development.1–6 Wound
healing can be considered in part a recapitulation of em-
bryogenesis. It involves complex spatial and temporal sig-
naling interactions that direct all cell behaviors, including
differentiation.7–13 Biological patterning involves the creation
of persistent patterns of a broad array of growth factors and
their modifying molecules, leading to functional organization
of multiple tissue types and organs. Extracellular matrix
(ECM) molecules such as proteoglycans can sequester growth
factors within the surrounding ECM or on the cell surface to
modify growth factor function either negatively or positive-
ly.14 Growth factor sequestration directly affects temporal and
spatial function by presenting growth factors at specific lo-
cations in the ECM or on the cell surface15–21 at picomolar to
nanomolar concentrations.22–26
We previously demonstrated the application of inkjet-based
biopatterning to print bio-inks of dilute aqueous solutions of
native growth factors onto native ECM substrates to make
persistent two-dimensional (2D) patterns.27–31 In this context,
the term 2D means surface patterning limited to printing bio-
inks onto thin substrates of ECM films, such as a 10-nm-thick
layer of fibrin crosslinked to glass slides. The growth factors
were immobilized to the ECM substrates by taking advantage
of the inherent native binding capacities between growth fac-
tors and ECM components.32,33 These patterns were then used
to direct cell fates in vitro, including migration, proliferation,
and differentiation, in register to printed patterns.27–31,34
The question remained whether such growth factor
patterning could translate into in vivo applications where
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three-dimensional (3D) constructs and patterns are required.
To investigate this, we adapted our 2D biopatterning meth-
odology to make 3D patterned constructs. Bio-inks were
printed onto a sheet of porous scaffold material whereby they
absorbed into and bound to the scaffold to form 3D patterned
constructs. The primary requirements for 3D printing sub-
strate materials are (1) open porosity and hydrophilicity for
absorbing and internalizing a surface-applied bio-ink; (2) in-
nate binding capacity for a broad range of growth factors and
their modifiers; and (3) appropriate physical characteristics
making them easy to handle during application. In addition,
for use in investigations focusing on the role of growth factors
in driving differentiation, these materials should possess rel-
atively ‘‘neutral’’ material properties that do not have strong
inherent stimulation capacity for any specific tissue type. It is
important to emphasize that many surgically created wound
sites do not require the use of scaffold materials that possess
the same biomechanical properties as the targeted tissue to be
regenerated because the scaffold is meant to be completely
remodeled. DermaMatrix (Synthes, West Chester, PA)
acellular dermal matrix fulfilled all these requirements. Der-
maMatrix is a human allograft material that maintains origi-
nal dermal ECM architecture. It contains a range of ECM
molecules, including collagens I and III, elastin, fibronectin,
glycosaminoglycans, and proteoglycans, many of which can
sequester or bind a broad range of growth factors and their
modifiers.
This article presents the adaptation of our 2D bioprinting
methodology to create persistent 3D spatial patterns of
growth factors and their modifiers in a delivery scaffold. The
bioprinting approach was demonstrated using printed bone
morphogenetic protein-2 (BMP-2)=DermaMatrix constructs
to spatially direct and restrict cellular differentiation down the
osteogenic lineage in vitro and bone formation in vivo in a
mouse calvarial defect model. Patterns of noggin, an inhibitor
of BMP-2,35 were also printed adjacent to the BMP-2 patterns
to investigate fine control over patterned response discrimi-
nation. The fidelity of spatial restriction of osteoblastic dif-
ferentiation in vitro and bone formation in vivo between
neighboring BMP-2 and noggin patterns improved in com-
parison with patterns without noggin. Importantly, osteo-
inductive responses to BMP were achieved with substantially
lower doses than generally reported.
Materials and Methods
In vitro—biopatterning
Bio-inks were printed using our custom 2D inkjet depo-
sition system that was described in detail previously.27 A
drop-on-demand piezoelectric inkjet printhead with a 30-mm-
diameter orifice (MicroFab Technologies, Plano, TX)was used
for all growth factor patterning. The center-to-center drop
spacing was set to 75 mm. To passivate the glass surface of the
inkjet, it was filled with 1mg=mL BSA (Sigma Chemical,
St. Louis, MO) and incubated for 10min. The jet was rinsed
three times with deionized water and filled immediately with
the bio-ink. The bio-inks consisted of human recombinant
BMP-2, noggin, growth and differentiation factor-5 (GDF-5),
and transforming growth factor-b1 (TGF-b1) (R&D Systems,
Minneapolis, MN), each diluted in 10mM sodium phosphate,
pH 7.4, to final concentrations of 50, 100, or 200 mg=mL.
In vitro dosing studies consisted of printing an array of
BMP-2 in varying concentrations as 1mm1mm squares
spaced 1mm apart on a 10mm10mm piece of ultrathin
(200–400 mm thick) DermaMatrix derived from human
acellular dermis (gift from Synthes). The bio-ink concentra-
tions were held constant at 50, 100, or 200mg=mL and surface
concentration was controlled by varying the number of over-
prints (OPs),27,31,34 including 2, 12, 22, and 32 OPs. Gradient
patterns of Cy5-BMP-2 on DermaMatrix were also printed to
FIG. 1. Custom inkjet print-
ing system (A) used to create
three-dimensional printed
constructs within DermaMa-
trix. (B, C) Growth factor
bioink droplets averaged 14 pl
(D). Color images available
online at www.liebertonline
.com=ten.
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demonstrate the use of overprinting to modulate deposited
concentration. Printed gradients were 1.5mm long and 1mm
wide, with 80 mm spacing of deposited drops.
For the single-dose patterns used in all other experiments,
bio-ink concentration was varied while maintaining a fixed
number of 12 OPs. Patterns of BMP-2, noggin, GDF-5, and
TGF-b1 were printed on DermaMatrix cut into 5-mm-
diameter disks using 5mm biopsy punches (MedExSupply
Medical Supplies, Monsey, NY). A small notch was cut into
one side of the DermaMatrix for registration purposes and the
printing was performed on the dermal side of the scaffold. A
semicircular pattern of BMP-2 was printed on one half of the
construct; the other contralateral half was left unprinted or
printed with noggin, GDF-5, or TGF-b1. For in vivo experi-
ments, nonprinted (NP) DermaMatrix disks were used as
additional controls. The printing setup used for these exper-
iments is shown in Figure 1. The DermaMatrix was placed on
the printing stages and was held in place during printing
using a vacuum chuck.
Pattern validation and persistence
Fluorescently labeled BMP-2 was utilized to validate pat-
tern printing on DermaMatrix. Fluorescent labeling of BMP-2
was performed as described previously.34 Briefly, BMP-2 was
labeled with monoreactive N-hydroxysuccinimide ester cya-
nine 5 dye (Cy5, synthesized in-house) following established
protocols.36 The Cy5-BMP-2 bio-inks were diluted in 10mM
sodium phosphate, pH 7.4, to the desired concentrations.
Patterns of the Cy5-BMP-2 were printed in the same
manner as previously described.31,34 For fluorescent-labeled
BMP-2 printed gradients, 120mg=mL Cy5-BMP-2 bio-ink was
used. After printing, the constructs were imaged using a Zeiss
Axioplan 2 epifluorescencemicroscopewith a Fluor 2.5, 0.12
numerical aperature (NA) objective, AxioCam MRm CCD
camera, and AxioVision acquisition software v. 4.3 (all mi-
croscope components and software from Carl Zeiss, Thorn-
wood, NY). The patterned constructs were then placed in
phosphate-buffered saline (PBS) for approximately 30min
and imaged again.
Radiolabeling was used to quantify the binding and de-
sorption of BMP-2 and noggin to determine the persistence of
these applied bio-inks over time. BMP-2 and noggin were
iodinated using a chloramine T method as described previ-
ously.34,37 The concentrations of the 125I-BMP-2 and 125I-
noggin were selected so that the surface concentrations
prepared using the blotting would be comparable to what
was inkjet printed. DermaMatrix samples were patterned by
placing 1mL of the prepared bio-ink onto the DermaMatrix
substrate and allowing it to dry. After determining the
quantity of 125I-labeled BMP-2 or 125I-noggin applied to each
DermaMatrix sample using a Cobra II auto-gamma counter
(Perkin-Elmer, Wellesley, MA), the slides were rinsed three
times in PBS and the amount of 125I-labeled components re-
tained was determined again. The DermaMatrix samples
were then placed in serum-free minimum essential alpha
medium (a-MEM) with 25mM HEPES, 0.02% sodium azide,
and 1% penicillin=streptomycin and stored at 378C for 24 h.
The radioactive counts were determined again and the serum-
free medium was replaced with serum-containing medium.
The 125I-BMP-2 and 125I-noggin DermaMatrix samples were
incubated in a-MEM containing 10% calf serum, the typical
serum concentration used for in vitro experiments and to ac-
count for the likelihood that serum constituents may impact
bio-ink binding retention. All acquired data were corrected to
account for radioactive decay.
Determination of osteoblast differentiation in vitro
Osteoblast differentiation was assessed via alkaline phos-
phatase (ALP) in register to applied patterns of bio-inks.
After patterning the disks of DermaMatrix, the constructs
were secured to the bottom of the wells of a 24-well plate
using sterile silicone grease, 1mL of PBS was added to each
construct, and the construct were placed in the incubator at
378C overnight. The constructs were then rinsed with 1mL of
PBS and seeded with cells. C2C12 myogenic precursor cells
were obtained from American Type Culture Collection
(Manassas, VA) and cultured according to the American
Type Culture Collection instructions in growth medium
(Dulbecco’s modified Eagle’s medium [high-glucose], with
10% calf serum and 1% penicillin=streptomycin; Invitrogen,
Carlsbad, CA). Each well was seeded with 200,000 cells in
growth medium and placed in a standard incubator (5%
CO2, 378C) for 48 h. After this culture period, the cells were
rinsed in PBS and stained for ALP activity using a leukocyte
ALP kit (product number 86C from Sigma Chemical) ac-
cording to the manufacturer’s instructions.
In vivo—calvarial defects and bone healing analysis
Sixty-eight normal male mice (C57BL-6J; Jackson, Bar
Harbor, ME), 8 weeks of age, were used in this study. Der-
maMatrix disks were prepared as described earlier with
BMP-2 on one half of the scaffold while the other half was
untreated (n¼ 10) or printed with noggin (n¼ 8), and the
constructs were placed in a 24-well plate with 1mL of PBS
and kept in the incubator at 378C until implantation, which
was within 2–4 days of the initial printing. Two separate
control groups consisted of 10 animals in which the defect
was left empty and 5 animals in which the defect was filled
with unprinted DermaMatrix disks. These groups served to
evaluate baseline healing inherent to the defect or to the
osteogenic properties of the unprinted DermaMatrix.
The mice were anesthetized and the scalp depilated and
cleaned prior to surgery. Under sterile conditions, a 5mm
circular bone defect was made in the skull using a 5.0mm
trephine (Fine Science Tools, Foster City, CA). One construct
was placed within each skull defect with the orientation of
the construct determined and assured using the notch that
was cut in the DermaMatrix disk opposite to the BMP-2-
printed side. Bone healing was assessed in representative
animals using microcomputed tomography (VivaCT40;
Scanco Medical, Easton, PA) analysis at 1 day, and 2, 4, and 8
weeks after surgery. After 4 or 8 weeks, animals were eu-
thanized and the skulls removed and fixed in 10% neutral
buffered formalin for subsequent analyses.
Traditional 2D radiographic images were collected from all
fixed skulls using a Faxitron (MX-20; Faxitron X-Ray Cor-
poration, Wheeling, IL), digitized, and measured with
Northern Eclipse software (Empix Imaging, Cheektowaga,
NY) to determine the remaining defect area. Photographs
were taken of each skull to assess the final placement of the
construct through identification of the notched side. Based on
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the notch placement, the area of bone formation in either the
BMP-2-treated or opposite notched (untreated or noggin
treated) half of the defect was determined by subtracting the
measured radiographic defect area from the geometric defect
area (9.8125mm2). Mean measurements of bone area were
compared between BMP-2-treated sides and the sides without
BMP treatment using ANOVA followed by a least significant
differences multiple comparisons test (SYSTAT, v9.0). Fol-
lowing radiographic analysis, skulls were decalcified in 10%
ethylenediaminetetraacetic acid, paraffin embedded, cut into
5-mm-thick sections, and stained with hematoxylin and eosin.
Results
In vitro experiments
Scanning electron micrographs of DermaMatrix are shown
in Figure 2A and B. We were able to print concentration-
modulated gradient patterns of Cy5-BMP-2 on DermaMatrix
(Fig. 2C). Cy5-BMP-2 was also printed on the right semicircle
of a 5-mm-diameter by 200-mm-thick disk of DermaMatrix
(Fig. 2D). The depth of bio-ink penetration into DermaMatrix
using Cy5-BMP-2 was determined to be on average of 75 mm
(range of 65–80 mm) by measuring the axial travel of the
piezoelectic z-stage from bottom-to-top of the 3D image
stack using a two-photon point scanning laser scanning mi-
croscope (data not shown). Cross-sectional scanning electron
microscopy (SEM) imaging of the DermaMatrix demon-
strated a closed epidermal surface (right side, Fig. 2B) and an
open-pore dermal surface (left side, Fig. 2B). The dermal side
was used for the printing surface, the cell seeding surface,
and the dura mater interface (printed dermal side was placed
against the dura in vivo).
Printed growth factor patterns must persist to be consid-
ered as valid solid-phase patterns. The binding and persis-
tence of solid-phase BMP-2 and noggin in DermaMatrix
(Fig. 3) was determined using our previously developed
methodology.31 BMP-2 bound to DermaMatrix in a dose-
FIG. 2. DermaMatrix as a three-
dimensional printing substrate. (A) Tiled
scanning electron micrograph of 5mm
DermaMatrix disk. (B) Scanning electron
micrograph of DermaMatrix cross section.
Right side represents epidermal layer. (C)
Fluorescent image of Cy5-bone morphoge-
netic protein-2 (BMP-2) printed in a gradient
upon DermaMatrix. (D) Fluorescent image
of Cy5-BMP-2 printed on half of 5mm
DermaMatrix disk.
FIG. 3. Binding and retention of printed BMP-2 and noggin
on DermaMatrix.
1752 COOPER ET AL.
dependent manner for BMP-2 concentrations of 0.11–
26.5 ng=mm2 applied (combined concentration of 125I-labeled
and unlabeled BMP-2). Applied surface concentrations in
units of ng=mm2 were calculated as previously described.27
Following PBS rinses to remove unbound BMP-2, an av-
erage of 90% of printed BMP-2 remained bound across all
printed concentrations (time zero on upper graph of Fig. 3).
After 24 h of incubation in medium at 378C, an average of
78.7% BMP-2 remained across all concentrations and subse-
quent BMP-2 released at a slower rate over the remaining 14
days of study such that *70% of bound BMP-2 remained.
Noggin also bound to DermaMatrix in a dose-dependent
manner for noggin concentrations applied between 0.091 and
53.78 ng=mm2 (combined concentration of 125I-labeled and
unlabeled noggin). Following PBS rinses to remove un-
bound noggin, an average of 83% of printed noggin re-
mained bound across all printed concentrations (time zero
on lower graph of Fig. 3). After 24 h of incubation in medium
at 378C, an average of 69% noggin remained across all con-
centrations, after which subsequent noggin released at a
slower rate over the remaining 14 days of study such that
*50% of bound noggin remained. All printed samples of
DermaMatrix used for subsequent in vitro and in vivo experi-
ments were therefore used only after a minimum of 2 days in
PBS.
Spatial control of osteoblastic differentiation of C2C12
cells seeded upon BMP-2-printed patterns of DermaMatrix
was demonstrated using ALP staining (Fig. 4). Increasing
concentrations of BMP-2 bio-inks (10, 50, or 200 mg=mL BMP-
2, 12 OPs each) were printed on the right side of each Der-
maMatrix scaffold disk, whereas the left sides of the scaffolds
represented NP controls (Fig. 4A–C). ALP staining increased
with increased amounts of bound BMP-2 (3.73, 18.65, and
74.6 ng total mass of BMP-2 per semicircular pattern). An
increase in sporadic staining off pattern was observed as
BMP-2 concentration increased, especially evident for the
200mg=mL dose. This loss of spatial control at high doses
suggests spillover effects, presumably caused by desorption
of BMP-2 from printed pattern and readsorption off pattern.
To improve spatial control of differentiation, subsequent
experiments involved printing one half of each DermaMatrix
disk with BMP-2 (200mg=mL) and printing the opposite
FIG. 4. BMP-2 printed on
DermaMatrix stimulates oste-
ogenic cell differentiation in
C2C12 cells. All DermaMatrix
pieces had right and left
semicircular halves printed
independently as labeled. Al-
kaline phosphatase (ALP)
staining (blue) shows in-
creased ALP expression with
increased doses of BMP-2 (A–
C). Comparison of different
protein combinations showed
that noggin was more capable
of inhibiting undesired ALP
staining (on the left side of the





factor (GDF-5) showed in-
creased ALP activity on the
left side of the DermaMatrix
(side not printed with BMP-2)
(G). C2C12 cells seeded ran-
domly onto DermaMatrix
show an ALP staining dose
response to printed BMP-2
(H). Higher concentrations of
BMP-2 are achieved by in-
creasing the number of bio-ink
overprints (OPs). Images are
representative of at least three
separate experiments. Color
images available online at
www.liebertonline.com=ten.
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half with modifiers of BMP-2 stimulation, including nog-
gin (50 mg=mL), transforming growth factor b1 (TGF-b1;
100 mg=mL), or GDF-5 (100 mg=mL; Fig. 4E–G). The 200
mg=mL dose of BMP-2 exhibited spillover effects resulting in
ALP-positive staining on theNP side of each implant (Fig. 4D).
This undesired ALP activity was efficiently inhibited by
printing noggin opposite to BMP-2 (Fig. 4E). TGF-b1 was not
an efficient inhibitor and appeared to enhanceALP expression
on the BMP-2 side (Fig. 4F). As an additional control, GDF-5,
which promotes ALP activity, was printed on the side oppo-
site of BMP-2 (Fig. 4G). This resulted in a complete filling of
the disk surface with ALP-positive cells. Figure 4H shows a
22 printed array of BMP-2 onDermaMatrix using increasing
OP of 50mg=mL BMP-2 bio-ink.
In vivo experiments
To demonstrate the translational potential of our printing
methodology, BMP-2- and noggin-printed constructs were
implanted in vivo. Printed BMP-2 patterns were oriented on
either the right or the left side of the defect mouse calvarial
defects. Constructs printed with BMP-2 showed evidence of
bone formation as early as 2 weeks postoperatively (Fig. 5A).
After locating the notch that was made in the DermaMatrix
opposite to the BMP-2 pattern, we identified that bone pref-
erentially formed in registration with the printed BMP-2
pattern. Further, the shape of the bone that formed by 4weeks
postoperatively was similar to the shape found 8 weeks after
implantation (Fig. 5B), indicating the temporal persistence of
spatial control.
Some animals received bilateral semicircular patterns of
the following combination pairs: (1) DermaMatrix NP on both
FIG. 5. Applying BMP-2-
printed DermaMatrix con-
structs in a critical-sized mouse
defect model to spatially con-
trol bone formation. A) Photo-
graph (left), radiograph
(center), and 3D CT (right) of
implanted skull 2 weeks post-
operative. B) 3D CT recon-
structions of one animal
2 weeks, 4 weeks, and 8 weeks
postoperative. Color images
available online at www
.liebertonline.com=ten.
FIG. 6. The effect of various applied patterns on bone fill in
register to applied pattern. Treatment groups were defects
with unfilled (Defect Control, n¼ 20), paired nonprinted
(NP) DermaMatrix disks (NP Control, n¼ 10), NP control
(n¼ 20) adjacent to BMP-2 (100mg=mL BMP-2, 12 OPs,
n¼ 20) pairs, and noggin (100 mg=mL BMP-2, 12 OPs, n¼ 18)
adjacent to BMP-2 (n¼ 18). Animals were sacrificed after 4
weeks and evaluated by radiography. Data are presented as
mean percentage of pattern fill standard error of the mean.
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semicircular sides; (2) DermaMatrix printed on one semicir-
cular side with BMP-2 (37.5 ng) and the other NP; (3) Der-
maMatrix printed on one semicircular side with BMP-2
(37.5 ng) and the other printed with noggin (37.5 ng); and (4)
no DermaMatrix construct (defect left unfilled). For BMP-2=
NP- and BMP-2=noggin-paired DermaMatrix disks, half of
the animals received the BMP-2 on the right side of the defect
and the other half on the left side. Animals were euthanized at
4 weeks and the percentage of pattern fill measured by radi-
ography was determined as follows: 1002D bone area
within applied semicircular pattern=total area of semicircular
pattern (total area¼ 9.8125mm2), where complete bone for-
mation in register to pattern is represented as 100% pattern fill
(Fig. 6). There was no effect due to the side of the calvarial
defect in which BMP-2 or noggin was placed ( p¼ 0.717);
therefore, side orientation was not separated for further
analysis. Limited healing of the defect occurred when the
defect remained completely untreated (15.87% 3.1% pattern
fill, n¼ 20 semicircular patterns; Fig. 6), primarily associated
with bone fill occurring from the calvarial defect perimeter.
The application of unprinted DermaMatrix disks resulted in a
significant increase in bone fill (40.9% 2.2% pattern fill,
n¼ 10) over the untreated defect control ( p< 0.0001), repre-
senting an approximate 2.6-fold increase in bone formation.
For DermaMatrix disk with paired BMP-2 and NP patterns,
BMP-2 patterns resulted in a pattern fill of 84.1% 3.7%
(n¼ 20) compared with the contralateral unprinted control of
58.7% 3.8% (n¼ 20), representing an increase in bone for-
mation of approximately 1.43-fold ( p¼ 0.001). Interestingly,
when NP patterns were compared between NP=NP and
FIG. 7. Hematoxylin and eosin (H&E) histological staining
for representative unprinted DermaMatrix (A) and Derma-
Matrix printed half with 100mg=mL BMP-2, 12 OPs (B) and
half left unprinted (C). Large black arrows denote calvarial
defect perimeter. IC, invading undefined cells; WB, woven
bone (magnification,50).
FIG. 8. Higher magnification of H&E histological staining
for representative DermaMatrix printed disks at 4 weeks (A)
and 8 weeks (B) using 100 mg=mL BMP-2, 12 OPs. IC, in-
vading undefined cells; WB, woven bone; BM, bone marrow
space; BV, blood vessel; C, endochondral bone; LB, lamellar
bone (magnification,200).
SPATIAL CONTROL OF BONE HEALING 1755
NP=BMP-2 pairs, therewas a significant increase in pattern fill
for NP patterns adjacent to BMP-2 patterns representing an
approximate 1.44-fold increase ( p¼ 0.007). These results
likely represent spillover from BMP-2 patterns to neighboring
contralateral non-BMP-2 patterns. When noggin=BMP-2-
paired DermaMatrix disks were applied, noggin (42.5%
4.89%, n¼ 18) eliminated the observed spillover from adjacent
BMP-2 patterns such that the percentage of pattern fill was
equivalent between NP (40.9% 2.2%) from NP=NP-paired
DermaMatrix disks ( p¼ 0.8). However, noggin patterns in-
duced a significant reduction in pattern fill in neighboring
BMP-2 patterns (56.9% 5.01%, n¼ 18) compared with
NP=BMP-2 pairs (84.1% 3.7%, n¼ 20; p< 0.001). These
results likely represent spillover from noggin patterns to
neighboring contralateral nonnoggin patterns. Nonetheless,
BMP-2 patterns from noggin=BMP-2 pairs resulted in greater
pattern fill compared with NP from NP=NP pairs ( p< 0.017).
Overall, bone formation occurring within the defect was in
register to BMP-2 patterns delivered.
Histological analysis was performed on samples at 2, 4, or
8 weeks postoperatively. Hematoxylin and eosin-stained
sections show that DermaMatrix alone does not result in
widespread bone formation (Fig. 7A). Bone formation was
spatially restricted to the BMP-2-printed half of the construct
(Fig. 7B) with essentially no bone formation in the unprinted
half (Fig. 7C). Importantly, not only was bone formation
restricted to the printed BMP-2 pattern in the x, y plane, but
also along the z axis.
High-magnification histological analysis demonstrated
that bone formation in the BMP-2-printed region formed
through endochondral bone formation. At 2 weeks (Fig. 8A),
cartilagenous pockets within BMP-2 patterns are evident with
some woven bone surrounding them. Extensive cellular in-
vasion occurred throughout the DermaMatrix. At 8 weeks
(Fig. 8B), woven bone formed within the DermaMatrix scaf-
fold essentially restricted to the BMP-2 pattern. Of special note
is that the ventral aspect of the DermaMatrix construct (Fig.
8B) shows remodeling of the woven bone into more mature
lamellar bone.
Discussion
We previously demonstrated that inkjet-based bioprinting
can be used to spatially pattern growth factors on ECM-
derived protein-based substrates, such as fibrin. Also, these
2D patterns persist and direct cell behavioral responses
in vitro in register to the patterns.27,30,31 We used an inkjet-
ting approach to pattern growth factors for the following
reasons: (1) deposited concentrations of growth factors can
be easily modulated by overprinting individual locations
with dilute bio-inks27,28; (2) inkjetting is completely pro-
grammable, so custom templates are not required to create
specific patterns, and therefore, experimental turn-around
times are relatively quick; (3) an almost endless variety and
combinations of bio-inks can be deposited with inkjets; (4)
inkjetting is scalable; (5) printing is noncontact; and (6) as
now described in this article, 2D inkjet patterning is directly
translatable to manufacturing 3D growth factor=scaffold
constructs. A possible disadvantage of using inkjetting is that
it has lower resolution than soft lithographic, photolitho-
graphic, or microfluidic protein patterning techniques.38,39
However, we have shown that the resolution achievable with
inkjet printing is sufficient to produce a patterned cellular
biological response.
Here we have demonstrated the extension of 2D bioprint-
ing to 3D by bioprinting BMP-2 onto DermaMatrix scaffolds
to form 3D constructs by absorption into and binding of BMP-
2 bio-ink within scaffolds. We have also demonstrated that
such 3D patterned BMP-2 spatially controlled osteoblast for-
mation in vitro. Osteoblast differentiation, evidenced by ALP
staining, occurred in register to printed BMP-2 patterns.
Spillover of ALP staining from BMP-2 patterns could be
minimized through the use of a contralateral copatterned
delivery of noggin, a BMP-2 inhibitor. Spillover effects of
BMP-2 and noggin off their respective printed patterns were
also observed in the cells contained off the constructs on the
underlying cell culturewell surfaces,with a decrease in overall
ALP staining observed for noggin and an increase in over-
all ALP staining observed for BMP-2. Whether this inhibition
of ALP activity reflects desorbed bio-inks diffusing off pattern
to impact these cells directly orwhether this represents de novo
signaling from cells on printed patterns to cells off pattern
remains unclear and the subject for future experiments. Fu-
ture experiments will consider improving the registration fi-
delity between patterned bio-inks and subsequent biological
responses by improving bio-ink binding retention. Alter-
native options include using engineered bio-inks designed for
improved binding, chemically crosslinking bio-inks to sub-
strates, and altering substrate chemistry to improve binding
of bio-inks.
Similarly, in vivo results demonstrated a direct translation
of in vitro findings to an in vivomodel inwhich bone formed in
register to printed BMP-2 and noggin as evidenced by ra-
diographic, microcomputed tomography, and histological
data. To our knowledge this is the first report where a
‘‘treatment group’’ can be compared with a control group for
tissue formation within the same construct. The ability to
spatially control tissue formationwithin a construct will allow
more precise in vivo experimentation consisting of internal
controls.
Further, using DermaMatrix printed with 100mg=mL
BMP-2 bio-ink resulted in a total delivered BMP-2 dose of
29.8 ng per semicircular pattern. This dose represents a total
of 37.3 ng applied. With*80% remaining within the scaffold
for delivery in vivo following the preincubation to remove
unbound BMP-2, the delivered dose was far below typical
threshold BMP-2 dosages.40 We are aware of only one other
report of similar BMP-2 dosing in a related calvarial model,41
which, however, used traditional PLGA scaffolds without
intraconstruct spatial control.
We have previously demonstrated that the bioactivity of
solid-phase growth factors can increase relative to liquid-
phase delivery,28 including BMP-2.31 Immobilization of both
BMP-2 and noggin are known to impact their respective
biological activities.33,42–45 For example, increased bioactiv-
ity of BMP-2 may be attributable in part to increased re-
sistance to proteolytic degradation, restricting diffusion,
and=or synergistic interaction between BMP-2 receptors and
integrins.33,46
DermaMatrix did not represent a completely neutral
scaffold for this particular study as evidenced by Derma-
Matrix NP controls exhibiting a higher percentage of bone
fill than untreated defect controls. This is likely due to the
osteoconductive nature of DermaMatrix as well as the pos-
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sibility of osteogenic properties due to residual growth fac-
tors not removed during the DermaMatrix manufacturing
process. Although bioprinting is compatible with many
other scaffold materials, DermaMatrix is a viable option for
clinical application. It has been previously shown to have
low immunogenicity47 and to vascularize following im-
plantation in humans.48 In this study, DermaMatrix was
shown to (1) support cell growth in vitro, (2) cellularize and
support neovascularization after implantation in vivo, and
(3) allow for bone formation. Further, printed DermaMatrix
constructs can be stored dry, which is compatible with
surgical logistics.
Beyond biopatterning’s use for basic biological studies,
this technology shows promise for direct translation to
clinical therapies. Inkjetting enables precise, repeatable
dosing and efficient use of expensive growth factors. As
bone tissue engineering seeks to regenerate diseased or
damaged bone, it is important to spatially restrict regener-
ation to avoid undesired stimulation of or impingement
upon surrounding nonbone tissues. The results reported
here suggest that bioprinting of BMP-2, alone or in combi-
nation with noggin, may be an effective option to spatially
control clinically relevant tissue boundary formation.49 For
example, craniosynostosis is the premature fusion of one of
more of the calvarial sutures, the narrow regions of non-
bone tissue between the bones of the skull. Sutures nor-
mally function in part to allow normal brain growth and to
transmit mechanical forces generated by mastication or
trauma.50,51 Craniosynostosis represents a failure to form a
functional boundary between bones.52 Our biopatterning
method represents an alternative approach to augment
surgical intervention53 for reestablishing these suture
boundaries for the purpose of reestablishing normal brain
growth vectors and intracranial volume.
Another application for biopatterning technologies is to
explore the various patterning cues that will help to establish
spatially defined boundaries between tissues within multi-
tissue anatomical units, such as muscle-to-bone or muscle-
to-tendon-to-bone. Our prior demonstration of selectively
driving a stem cell population to muscle–bone boundaries
in vitro31 represented a first-order feasibility of spatially con-
trolling muscle-to-bone attachments, which are anatomically
relevant in diverse tissues such as the tibia,54 the maxilla and
mandible,55,56 and the anterior deltoid.57
The bioprinting methodology presented here demon-
strated patterning in 200-mm (average)-thick scaffold sheets.
Larger or more complex 3D structures could be formed using
our method of layered scaffold assembly28,58 in which each
bioprinted layer would be individually patterned prior to
assembly. Further, multimaterial structures could be created
using different scaffold materials in different layers. Such
constructs could also be used in conjunction with a cell
therapy.
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